Biomarin Pharmaceutical (BMRN) Change in Accured Expenses (2009 - 2026)

Biomarin Pharmaceutical's Change in Accured Expenses history runs 18 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 427.83% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (down 63.12% YoY) and the FY2025 annual result came in at $14.9 million, up 0.73% from the prior year.
• Change in Accured Expenses was $8.7 million for Q1 2026 at Biomarin Pharmaceutical, up from -$7.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $73.1 million in Q3 2022 and bottomed at -$78.1 million in Q1 2022.
• A 5-year average of $9.8 million and a median of $4.5 million in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 3491.62% — and 2024, when it jumped 2212.28%.
• Biomarin Pharmaceutical's Change in Accured Expenses stood at $62.3 million in 2022, then dropped by 12.45% to $54.5 million in 2023, then tumbled by 91.69% to $4.5 million in 2024, then slumped by 254.96% to -$7.0 million in 2025, then surged by 223.94% to $8.7 million in 2026.
• Business Quant data shows BMRN's Change in Accured Expenses at $8.7 million in Q1 2026, -$7.0 million in Q4 2025, and $16.4 million in Q3 2025.